MétaCan
Menu
Back to cohort

Metformin Activates Resident Neural Stem and Progenitor Cells, Reduces Inflammation and Improves Functional Recovery Following Spinal Cord Injury

2021· article· en· W3172368633 on OpenAlexaff
Emily Gilbert, Tarlan Kehtari, Cindi M. Morshead

Bibliographic record

VenueThe FASEB Journal · 2021
Typearticle
Languageen
FieldNeuroscience
TopicNeurogenesis and neuroplasticity mechanisms
Canadian institutionsMuscular Dystrophy CanadaUniversity of Toronto
Fundersnot available
KeywordsMetforminSpinal cord injuryNeurogenesisProgenitor cellMedicineInflammationNeuroprotectionNeural stem cellPopulationPharmacologyProgenitorStem cellNeuroscienceSpinal cordInternal medicineBiologyCell biologyInsulin

Abstract

fetched live from OpenAlex

The mammalian spinal cord contains a population of neural stem and progenitor cells (NSPCs) located within the periventricular region lining the central canal. These cells are primarily quiescent under homeostatic conditions and are activated following injury, however, this response is not sufficient to support functional recovery in mammals. We propose that enhancing resident NSPC activation is a promising approach to promote neurorepair and improve functional outcomes following spinal cord injury (SCI). The FDA‐approved drug metformin has demonstrated efficacy in promoting functional recovery following brain injury through pleiotropic effects including NSPC activation, increased neurogenesis and oligodendrogenesis and modulation of the injury microenvironment including the inflammatory response. We hypothesize that metformin administration will promote functional recovery following SCI concomitant with activation of NSPCs and reduced inflammation. In a first series of in vitro experiments, we found that metformin significantly increases the size of the NSPC pool in females, but not males; increases neurogenesis in males and enhances oligodendrogenesis in both sexes. We next examined the effect of metformin treatment following SCI. Metformin was delivered to mice for 14 days starting immediately following SCI or starting at 7 days after SCI. Mice were tested on a skilled walking test and using gait analysis at 1 and 2 weeks following the start of metformin treatment. Mice that received metformin starting at the time of injury recovered motor function by 2 weeks post‐treatment however, delayed administration was not effective at improving functional outcomes. Interestingly, the functional outcomes observed in both treatment paradigms were correlated with metformin's effect on inflammation, as measured by the numbers of Iba1+ microglia/macrophages. In mice that received metformin immediately post‐SCI, Iba1+ cells were significantly reduced compared to vehicle‐treated SCI mice. Delayed metformin treatment did not lead to reduced inflammation relative to vehicle‐treated SCI mice. Together, these results support metformin as a viable therapeutic strategy to expand and enhance NSPCs, decrease inflammation and enhance functional outcomes when administered in the acute phase following SCI.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.039
GPT teacher head0.262
Teacher spread0.223 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe FASEB JournalSame topicNeurogenesis and neuroplasticity mechanismsFrench-language works237,207